SynthesisFrontiers in nutrition2025
Harnessing probiotic-metformin synergy: targeting the gut-microbiota metabolism axis to ameliorate polycystic ovary syndrome.
Synthesis in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus (T2DM) are interrelated through insulin resistance (IR) and gut microbiota dysbiosis. This review evaluates the synergistic efficacy and mechanisms of a combined probiotic and metformin regimen in the management of PCOS, with a specific focus on the gut-ovary-metabolism axis. Methods: A systematic literature search was conducted following PROSPERO (ID: CRD420251143914) registration across PubMed, EMBASE, Web of Science, the China National Knowledge Infrastructure (CNKI), the Wanfang Database, and the VIP Database, prioritizing randomized controlled trials and retrospective studies. Results: The combination therapy suggests improved outcomes compared to metformin monotherapy, yielding significant improvements in metabolic, hormonal, and reproductive function. Crucially, probiotics alleviated metformin-induced gastrointestinal adverse effects, thereby enhancing treatment adherence. The proposed underlying mechanisms involve a synergistic restoration of gut microbial homeostasis, increased production of short-chain fatty acids, reinforcement of the intestinal barrier, and potentiated activation of the AMP-Activated Protein Kinase (AMPK) pathway. Conclusion: As an adjunct supplement to metformin, probiotics represent a novel, evidence-supported therapeutic strategy for PCOS. This approach offers enhanced efficacy and tolerability, with potential implications for a broader spectrum of metabolic disorders including T2DM; however, given the current paucity of related studies, conclusions should be drawn cautiously. Systematic review registration: [https://www.crd.york.ac.uk/prospero/], identifier [CRD420251143914].
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.